Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18933878 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | No | No |
| 18518014 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | February 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 18065194 | GENETIC ELEMENT E3 FOR ENHANCED INTRACELLULAR EXPRESSION OF TARGET PROTEIN ENCODED IN RNA THERAPEUTICS | December 2022 | December 2023 | Allow | 12 | 1 | 0 | No | No |
| 18060179 | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | November 2022 | July 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18047341 | EUKARYOTIC CELLS COMPRISING ADENOVIRUS-ASSOCIATED VIRUS POLYNUCLEOTIDES | October 2022 | October 2024 | Allow | 24 | 4 | 0 | Yes | No |
| 18046291 | Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors | October 2022 | July 2024 | Allow | 21 | 2 | 1 | No | No |
| 17932996 | METHODS AND COMPOSITIONS FOR REDUCING PATHOGENIC ISOFORMS | September 2022 | March 2024 | Allow | 18 | 1 | 1 | No | No |
| 17815035 | CIRCULAR RNA MOLECULE AND USE THEREOF IN TARGETED DEGRADATION OF PROTEIN OF INTEREST | July 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17870754 | UNC13A ANTISENSE OLIGONUCLEOTIDES | July 2022 | August 2024 | Allow | 25 | 3 | 1 | Yes | No |
| 17574163 | ALLELE-SPECIFIC INACTIVATION OF MUTANT HTT VIA GENE EDITING AT CODING REGION SINGLE NUCLEOTIDE POLYMORPHISMS | January 2022 | December 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17609334 | METHODS FOR TREATING MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES TO CD49D | November 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17436451 | INTRACELLULAR TARGETING OF MOLECULES | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17433568 | APPLICATION OF CIRCULAR RNA IN PREPARING DRUG FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | August 2021 | April 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17433528 | FRAGILE X MENTAL RETARDATION PROTEIN INTERFERING OLIGONUCLEOTIDES AND METHODS OF USING SAME | August 2021 | May 2025 | Abandon | 45 | 1 | 0 | Yes | No |
| 17425853 | COMPOSITION FOR ADMINISTERING AND RELEASING OLIGONUCLEOTIDES | July 2021 | April 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17424843 | ANTISENSE OLIGONUCLEOTIDES TARGETING SCN2A RETAINED INTRONS | July 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17423757 | RNA-EDITING OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17423620 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER`S CONGENITAL AMAUROSIS | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17366946 | Prostate Neoantigens And Their Uses | July 2021 | January 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17251549 | OLIGONUCLEOTIDE-BASED PROTEOLYSIS TARGETING CHIMERA | June 2021 | April 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17353572 | DONOR T-CELLS WITH KILL SWITCH | June 2021 | March 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17297521 | MODULATION OF SPTLC1 VIA RECOMBINANT ADENO-ASSOCIATED VECTORS | May 2021 | April 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17297045 | METHODS FOR DIAGNOSING AND/OR TREATING ACUTE OR CHRONIC LIVER, KIDNEY OR LUNG DISEASE | May 2021 | January 2025 | Allow | 43 | 1 | 1 | No | No |
| 17297017 | VDAC INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | May 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17296530 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL8 | May 2021 | May 2025 | Allow | 60 | 2 | 1 | No | No |
| 17291884 | Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17290758 | METHOD FOR PREVENTING OXIDATION OF POLYPHENOL BY MEANS OF APTAMER, MATERIAL THEREOF, AND USE THEREOF | May 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17285399 | DISRUPTING GENOMIC COMPLEX ASSEMBLY IN FUSION GENES | April 2021 | April 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17229040 | USE OF AKT INHIBITORS IN OPHTHALMOLOGY | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17191870 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | March 2021 | December 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17272783 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | March 2021 | December 2024 | Allow | 45 | 2 | 0 | No | No |
| 17272269 | COMPOSITIONS AND METHODS FOR USE IN CONTROLLING MOSQUITO-BORNE VIRUSES | February 2021 | March 2024 | Allow | 37 | 1 | 0 | No | No |
| 17268390 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY | February 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17268068 | COMPOUNDS OF CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | February 2021 | October 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17171050 | Aptamer Compositions and Methods of Use Thereof | February 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17162045 | COMPOSITION FOR INHIBITING CTGF EXPRESSION | January 2021 | October 2024 | Allow | 45 | 1 | 1 | No | No |
| 17258288 | VIRUS-LIKE PARTICLES AND USE THEREOF | January 2021 | May 2024 | Allow | 40 | 1 | 0 | No | No |
| 17257951 | NOVEL METHOD TO ENGINEER TRANSPLANTABLE HUMAN TISSUES | January 2021 | November 2024 | Allow | 46 | 2 | 1 | No | No |
| 17252947 | PROTEINS THAT INHIBIT CAS12A (CPF1), A CRIPR-CAS NUCLEASE | December 2020 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17251482 | ENGINEERED UNTRANSLATED REGIONS (UTR) FOR AAV PRODUCTION | December 2020 | March 2024 | Allow | 39 | 1 | 0 | No | No |
| 17059815 | COMPOSITIONS AND METHODS FOR TREATMENT OF DOMINANT RETINITIS PIGMENTOSA | November 2020 | September 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17058911 | METHOD TO PRODUCE CONDITIONALLY APOPTOTIC CELLS | November 2020 | March 2025 | Allow | 52 | 2 | 0 | No | No |
| 17057398 | BASE EDITORS AND USES THEREOF | November 2020 | April 2024 | Allow | 41 | 1 | 1 | No | No |
| 17055942 | MOLECULAR TOOLS AND METHODS FOR TRANSGENE INTEGRATION AND THEIR TRANSPOSITION DEPENDENT EXPRESSION | November 2020 | December 2024 | Allow | 49 | 2 | 0 | Yes | No |
| 17047615 | MULTIFUNCTIONAL NUCLEIC ACID REPORTER CONSTRUCTS | October 2020 | March 2025 | Allow | 53 | 2 | 0 | No | No |
| 16606443 | P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION | October 2019 | October 2024 | Allow | 60 | 1 | 1 | No | No |
| 16310515 | CRISPR-CAS SYSTEM, MATERIALS AND METHODS | December 2018 | January 2025 | Abandon | 60 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SULLIVAN, STEPHANIE LAUREN works in Art Unit 1635 and has examined 46 patent applications in our dataset. With an allowance rate of 58.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner SULLIVAN, STEPHANIE LAUREN's allowance rate of 58.7% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SULLIVAN, STEPHANIE LAUREN receive 1.28 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SULLIVAN, STEPHANIE LAUREN is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.9% benefit to allowance rate for applications examined by SULLIVAN, STEPHANIE LAUREN. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 40.0% of applications are subsequently allowed. This success rate is in the 89% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 83.3% of cases where such amendments are filed. This entry rate is in the 97% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.4% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.